Treace Medical Concepts Inc
NASDAQ:TMCI
Intrinsic Value
Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. [ Read More ]
The intrinsic value of one
TMCI
stock under the Base Case scenario is
19.22
USD.
Compared to the current market price of 10.67 USD,
Treace Medical Concepts Inc
is
Undervalued by 44%.
Treace Medical Concepts Inc's market capitalization is 658.9m USD.
TMCI stock price is 10.67 USD.
TMCI stock price (10.67 USD) is 44% less than its Intrinsic Value (19.22 USD).
TMCI. Open DCF Valuation
TMCI stock price (10.67 USD) is 44% less than its Relative Value (19.22 USD). Open Relative Valuation
TMCI has upside potential of 52% compared to the average analyst price target.
Open Wall St Estimates
TMCI's Revenue has grown by an exceptional 32% over the past 12 months.
TMCI's Revenue is forecast to grow at a rate of 19% per year over the next 3 years.
TMCI's ROE (Return on Equity) has significantly decreased in the last 3 years from 733% to -50%.
TMCI's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 3% to -55%.
TMCI has positive three-year average ROE (Return on Equity): 23%. The company is efficient at transforming stockholders' equity into net income.
TMCI's long-term assets (252m USD) exceed its long-term liabilties (114m USD).
TMCI has negative Operating Income for the last twelve months.
TMCI has negative Net Income for the last twelve months.
TMCI's ROE (Return on Equity) for the past 12 months is negative and is equal to -50%.
TMCI's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -55%.
TMCI has negative Net Debt. This means that the company has more cash and short-term investments (123m USD) than debt (53m USD).
TMCI has positive Gross Profit for the last twelve months.
TMCI's Revenue has been growing by an exceptional 48% per year for the last 3 years.
TMCI's D/E (Debt to Equity) is very low and is equal to 0.38.
TMCI's Altman Z-Score is very high and is equal to 3.61.
TMCI has negative Free Cash Flow for the last twelve months.
TMCI has negative three-year average ROIC (Return on Invested Capital): -49%. The company is not efficient at using invested capital to generate operating income.
TMCI's short-term assets (198m USD) exceed its short-term liabilties (45m USD).
TMCI doesn't generate enough operating income (-51m USD) to safely cover interest payments on its debt (5m USD).
Valuation Backtest
Treace Medical Concepts Inc
Run backtest to discover the historical profit from buying and selling
TMCI
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Treace Medical Concepts Inc
Balance Sheet Decomposition
Treace Medical Concepts Inc
| Current Assets | 198.4m |
| Cash & Short-Term Investments | 123.2m |
| Receivables | 38.1m |
| Other Current Assets | 37.1m |
| Non-Current Assets | 53.5m |
| PP&E | 31.6m |
| Intangibles | 21.8m |
| Other Non-Current Assets | 146k |
| Current Liabilities | 45m |
| Accounts Payable | 11.8m |
| Accrued Liabilities | 30.2m |
| Other Current Liabilities | 3m |
| Non-Current Liabilities | 68.9m |
| Long-Term Debt | 53m |
| Other Non-Current Liabilities | 15.9m |
Earnings Waterfall
Treace Medical Concepts Inc
|
Revenue
|
187.1m
USD
|
|
Cost of Revenue
|
-35.2m
USD
|
|
Gross Profit
|
151.9m
USD
|
|
Operating Expenses
|
-203.4m
USD
|
|
Operating Income
|
-51.4m
USD
|
|
Other Expenses
|
1.9m
USD
|
|
Net Income
|
-49.5m
USD
|
Free Cash Flow Analysis
Treace Medical Concepts Inc
TMCI Profitability Score
Profitability Due Diligence
Treace Medical Concepts Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
Score
Treace Medical Concepts Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
TMCI Solvency Score
Solvency Due Diligence
Treace Medical Concepts Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
Treace Medical Concepts Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TMCI Price Targets Summary
Treace Medical Concepts Inc
According to Wall Street analysts, the average 1-year price target for
TMCI
is 16.17 USD
with a low forecast of 14.14 USD and a high forecast of 18.9 USD.
Ownership
TMCI Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
TMCI Price
Treace Medical Concepts Inc
| Average Annual Return | -4.64% |
| Standard Deviation of Annual Returns | 25.46% |
| Max Drawdown | -83% |
| Market Capitalization | 658.9m USD |
| Shares Outstanding | 61 755 100 |
| Percentage of Shares Shorted | 5.47% |
Company Profile
Treace Medical Concepts Inc
Country
Industry
Market Cap
Dividend Yield
Description
Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. The company is headquartered in Ponte Vedra, Florida and currently employs 248 full-time employees. The company went IPO on 2021-04-23. The firm is focused on strategic product development activities that improve surgical efficiencies and patient outcomes. The firm's proprietary Lapiplasty 3-dimensional (3D) Bunion Correction System, which is a combination of instruments, implants and surgical methods designed to correct all three dimensions of the bunion deformity, address the root cause of the bunion deformity. The Lapiplasty System combines novel surgical approach, the Lapiplasty Procedure, with its procedural instrumentation and single-use implant kits. The Lapiplasty Procedure is designed to rotate the entire metatarsal bone into normal anatomical position in all three dimensions, eliminating the bump and restoring normal anatomy. The Lapiplasty Procedure can be performed in either hospital outpatient or ambulatory surgery center settings. The firm's brands include Lapiplasty, Fast Grafter and Plantar Python.
Contact
IPO
Employees
Officers
The intrinsic value of one
TMCI
stock under the Base Case scenario is
19.22
USD.
Compared to the current market price of 10.67 USD,
Treace Medical Concepts Inc
is
Undervalued by 44%.
You don't have any saved screeners yet
